- Eloxx Pharmaceuticals Inc To Host Investor and Analyst Call on Alport Syndrome TranscriptJun 27, 2023
- Eloxx Pharmaceuticals Inc Annual Shareholders Meeting TranscriptJun 22, 2023
- Eloxx Pharmaceuticals Inc at Oppenheimer Healthcare Conference (Virtual) TranscriptMar 13, 2023
- Eloxx Pharmaceuticals Inc Topline ELX-02 Phase 2 Combination Results Call TranscriptSep 14, 2022
- Eloxx Pharmaceuticals Inc Topline ELX-02 Phase 2 Results Call and Webcast TranscriptNov 17, 2021
- Eloxx Pharmaceuticals Inc Analyst Call on Cystic Fibrosis Programs TranscriptOct 12, 2021
- Eloxx Pharmaceuticals, Inc., Zikani Therapeutics, Inc. - M&A Call TranscriptApr 01, 2021
- Q4 2020 Eloxx Pharmaceuticals Inc Earnings Call TranscriptMar 11, 2021$154.8 (+2.65%)Earnings
- Q3 2020 Eloxx Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2020$108.8 (+4.21%)Earnings
- Q2 2020 Eloxx Pharmaceuticals Inc Earnings Call TranscriptAug 06, 2020$123.6 (-6.93%)Earnings
- Eloxx Pharmaceuticals Inc Annual Shareholders Meeting TranscriptMay 20, 2020
- Q1 2020 Eloxx Pharmaceuticals Inc Earnings Call TranscriptMay 07, 2020$116.4 (+14.12%)Earnings
- Q4 2019 Eloxx Pharmaceuticals Inc Earnings Call TranscriptMar 05, 2020$138 (-9.92%)Earnings
- Eloxx Pharmaceuticals, Inc. - Special Call TranscriptJan 14, 2020
- Q3 2019 Eloxx Pharmaceuticals Inc Earnings Call TranscriptNov 05, 2019$262 (-6.89%)Earnings
- Q2 2019 Eloxx Pharmaceuticals Inc Earnings Call TranscriptAug 07, 2019$242.8 (-9.40%)Earnings
- Q1 2019 Eloxx Pharmaceuticals Inc Earnings Call TranscriptMay 09, 2019$474 (+7.63%)Earnings
- Eloxx Pharmaceuticals Inc at Barclays Global Healthcare Conference TranscriptMar 14, 2019
- Q4 2018 Eloxx Pharmaceuticals Inc Earnings Call TranscriptMar 08, 2019$470.4 (+1.55%)Earnings
Eloxx Pharmaceuticals Inc Topline ELX-02 Phase 2 Combination Results Call Transcript
Good afternoon. My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Eloxx Pharmaceuticals Conference Call. (Operator Instructions) Mr. John Woolford, Head of Investor Relations, you may begin your conference.
Thank you, operator. Good afternoon, and thank you to everyone who has joined today's call and webcast to discuss topline ELX-02 cystic fibrosis Phase II combination clinical trial results. A press release detailing the results was issued this afternoon and is currently available at www.eloxxpharma.com. An audio archive of the webcast will be available on Eloxx Pharmaceuticals website in the Investor Relations section later today. Also, please note that there are slides to accompany today's event. These slides are also available on the IR website.
Before we begin with prepared remarks, turning to Slide 2, I need to remind you that we will be making forward-looking statements during this teleconference that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)